Chardan analyst Keay Nakae upgraded Allurion Technologies (ALUR) to Buy from Neutral with a $3 price target The company obtained FDA approval for its gastric balloon system, featuring the Allurion Smart Capsule, the analyst tells investors in a research note. The firm believes the FDA approval “significantly increases the options” available to management going forward to support execution of its business plan.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALUR:
- Allurion Wins FDA Approval for Gastric Balloon System
- Allurion Technologies receives FDA approval for gastric balloon system
- Allurion announces partnership with Bionut to offer discounted Mounjaro
- Allurion Technologies sees Q4 revenue $3.3M-$3.7M, consensus $2.95M
- Allurion Technologies files to sell 5.99M shares of common stock for holders